Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas

KRASG12C inhibitors have revolutionized the clinical management of patients with KRASG12C-mutant lung adenocarcinoma. However, patient exposure to these inhibitors leads to the rapid onset of resistance. In this study, we have used genetically engineered mice to compare the therapeutic efficacy and...

Full description

Bibliographic Details
Main Authors: Marina Salmón, Ruth Álvarez-Díaz, Coral Fustero-Torre, Oksana Brehey, Carmen G. Lechuga, Manuel Sanclemente, Fernando Fernández-García, Alejandra López-García, María Carmen Martín-Guijarro, Sandra Rodríguez-Perales, Emily Bousquet-Mur, Lucía Morales-Cacho, Francisca Mulero, Fátima Al-Shahrour, Lola Martínez, Orlando Domínguez, Eduardo Caleiras, Sagrario Ortega, Carmen Guerra, Monica Musteanu, Matthias Drosten, Mariano Barbacid
Format: Article
Language:English
Published: American Society for Clinical Investigation 2023-04-01
Series:The Journal of Clinical Investigation
Subjects:
Oncology
Online Access:https://doi.org/10.1172/JCI164413

Internet

https://doi.org/10.1172/JCI164413

Similar Items